Clinical Trial Update: Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of pembrolizumab and olaparib for relapsed or refractory peripheral T-cell lymphoma, currently recruiting in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | Phase 2 | Status: RECRUITING